Kenvue (KVUE) Set to Release Earnings on Friday

Kenvue (NYSE:KVUE) will likely be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect Kenvue to announce earnings of $0.2915 per share and revenue of $3.86 billion for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 9:30 AM ET.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same period last year, the firm earned $0.29 earnings per share. Kenvue’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, analysts expect Kenvue to post $1.14 EPS for the current fiscal year and $1.23 EPS for the next fiscal year.

Kenvue Stock Down 0.4%

KVUE stock opened at $19.41 on Wednesday. The stock’s 50 day simple moving average is $18.38 and its 200 day simple moving average is $18.15. Kenvue has a fifty-two week low of $14.02 and a fifty-two week high of $20.13.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were given a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.3%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on KVUE shares. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. UBS Group lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Nine research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.60.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.